AffiliationCancer Research Campaign Department of Medical Oncology, Christie Hospital, Manchester, UK.
MetadataShow full item record
AbstractDuring the past 5 years, ifosfamide has been used increasingly in combination chemotherapy for small cell lung cancer (SCLC). The high activity and favorable toxicity spectrum (with the uroprotector mesna) will encourage further use. A policy of no dosage reduction is feasible in patients receiving combination chemotherapy with ifosfamide given as a 24-hour intravenous (IV) infusion, which is much more convenient than the more commonly used 4- to 5-day fractionated regimen. This policy has resulted in actual 2-year survivals of 22% to 33% among SCLC patients not intensively staged. The stability of ifosfamide and its high bioavailability have allowed its use in chronic, 7-day ambulatory IV infusions, with decreased toxicity and hospitalization. Recently, oral and subcutaneous administration also have been tried, again allowing outpatient treatment. The first studies with hemopoietic growth factor support, eg, granulocyte colony-stimulating factor, conducted with combination chemotherapy with ifosfamide-containing regimens in SCLC, demonstrated significant reduction in neutropenia, infections, and antibiotic use. It is clear that the dosage of ifosfamide can be intensified in the future. The broad versatility of the drug will allow interesting new studies, including those to be conducted with outpatients.
CitationNovel approaches with ifosfamide in small cell lung cancer. 1992, 19 (1 Suppl 1):68-77 Semin Oncol
JournalSeminars in Oncology
- Weekly alternating non-cross-resistant chemotherapy for small cell lung cancer with a good prognosis: a study of the Hellenic Cooperative Oncology Group.
- Authors: Skarlos DV, Samantas E, Pectasides D, Pavlidis N, Kalofonos C, Klouvas G, Panoussaki E, Tsiakopoulos E, Poulakis N, Fountzilas G
- Issue date: 1999 Feb
- Ifosfamide-based chemotherapy for previously treated lung cancer patients.
- Authors: Chen YM, Liu JM, Wu MF, Wu HW, Lin WC, Tsai CM, Perng RP, Whang-Peng J
- Issue date: 1998 Jul
- Standard- and high-dose etoposide, ifosfamide, carboplatin, and epirubicin in 100 patients with small-cell lung cancer: a mature follow-up report.
- Authors: Fetscher S, Brugger W, Engelhardt R, Kanz L, Hasse J, Frommhold H, Lange W, Mertelsmann R
- Issue date: 1999 May
- Overview of ifosfamide in small cell lung cancer.
- Authors: Ettinger DS
- Issue date: 1992 Feb
- Overview of ifosfamide in small cell and non-small cell lung cancer.
- Authors: Johnson DH
- Issue date: 1990 Apr